Antiplatelets and PPIs: Controversies and Choices of Agents

35

description

Antiplatelets and PPIs: Controversies and Choices of Agents. Thank you for taking the pre-assessment. To assess learning, these questions will be repeated at the end of the activity. Statin and Clopidogrel PK/PD Interaction Did Not Translate to Clinical Effect. - PowerPoint PPT Presentation

Transcript of Antiplatelets and PPIs: Controversies and Choices of Agents

Page 1: Antiplatelets and PPIs: Controversies and Choices of Agents
Page 2: Antiplatelets and PPIs: Controversies and Choices of Agents
Page 3: Antiplatelets and PPIs: Controversies and Choices of Agents
Page 4: Antiplatelets and PPIs: Controversies and Choices of Agents
Page 5: Antiplatelets and PPIs: Controversies and Choices of Agents
Page 6: Antiplatelets and PPIs: Controversies and Choices of Agents
Page 7: Antiplatelets and PPIs: Controversies and Choices of Agents
Page 8: Antiplatelets and PPIs: Controversies and Choices of Agents
Page 9: Antiplatelets and PPIs: Controversies and Choices of Agents
Page 10: Antiplatelets and PPIs: Controversies and Choices of Agents
Page 11: Antiplatelets and PPIs: Controversies and Choices of Agents
Page 12: Antiplatelets and PPIs: Controversies and Choices of Agents
Page 13: Antiplatelets and PPIs: Controversies and Choices of Agents
Page 14: Antiplatelets and PPIs: Controversies and Choices of Agents
Page 15: Antiplatelets and PPIs: Controversies and Choices of Agents
Page 16: Antiplatelets and PPIs: Controversies and Choices of Agents
Page 17: Antiplatelets and PPIs: Controversies and Choices of Agents
Page 18: Antiplatelets and PPIs: Controversies and Choices of Agents
Page 19: Antiplatelets and PPIs: Controversies and Choices of Agents
Page 20: Antiplatelets and PPIs: Controversies and Choices of Agents
Page 21: Antiplatelets and PPIs: Controversies and Choices of Agents
Page 22: Antiplatelets and PPIs: Controversies and Choices of Agents
Page 23: Antiplatelets and PPIs: Controversies and Choices of Agents
Page 24: Antiplatelets and PPIs: Controversies and Choices of Agents
Page 25: Antiplatelets and PPIs: Controversies and Choices of Agents
Page 26: Antiplatelets and PPIs: Controversies and Choices of Agents
Page 27: Antiplatelets and PPIs: Controversies and Choices of Agents
Page 28: Antiplatelets and PPIs: Controversies and Choices of Agents
Page 29: Antiplatelets and PPIs: Controversies and Choices of Agents
Page 30: Antiplatelets and PPIs: Controversies and Choices of Agents
Page 31: Antiplatelets and PPIs: Controversies and Choices of Agents
Page 32: Antiplatelets and PPIs: Controversies and Choices of Agents
Page 33: Antiplatelets and PPIs: Controversies and Choices of Agents
Page 34: Antiplatelets and PPIs: Controversies and Choices of Agents
Page 35: Antiplatelets and PPIs: Controversies and Choices of Agents